Workflow
Bio-Rad(BIO)
icon
Search documents
Bio-Rad(BIO) - 2024 Q3 - Quarterly Results
2024-10-30 20:17
Exhibit 99.1 Press Release Bio-Rad Reports Third-Quarter 2024 Financial Results HERCULES, Calif.—October 30, 2024 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2024. Third-quarter 2024 total net sales were $649.7 million, an increase of 2.8 percent compared to $632.1 million reported for the third quarter of 2023. On a currency-neutral basis, quarterl ...
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS
Prnewswire· 2024-10-30 10:30
MINNEAPOLIS, Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights First quarter organic revenue increased by 4% (5% reported) to $289.5 million. GAAP earnings per share (EPS) was $0.21 versus $0.31 one year ago. Delivered adjusted EPS of $0.42 compared to $0.41 one year ago. Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostic ...
What to Expect From These 3 MedTech Stocks This Earnings Season
ZACKS· 2024-10-29 16:31
With the third-quarter earnings season in full swing, it's going to be a pivotal week for numerous firms within the medical device sector. The latest Earnings Preview report indicates strong earnings and revenue growth within the Medical sector. The projected top and bottom-line improvements can be attributed to sustained demand for medical products and services, and favorable pricing strategies, which are likely to offset the shortcomings generated from worldwide geopolitical issues, high-interest expense ...
Tonix Pharmaceuticals to Present at BIO-Europe® 2024
GlobeNewswire News Room· 2024-10-29 12:00
CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, will present at BIO-Europe®, being held November 4-6, 2024, in Stockholm, Sweden. The presentation will take place on Monday, November 4, 2024, at 1:00 p.m. CET. To schedule a meeting wi ...
BIO-key Secures $910,000 Order to Upgrade Long-Time Financial Services Customer to Enhanced Biometric Customer Identification Technology
GlobeNewswire News Room· 2024-10-29 10:27
HOLMDEL, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication, announced that it has received a $910,000 order from a long-term financial services customer to upgrade to BIO-key's "fingerprint only" Biometric Customer Identification Technology. The technology enhancem ...
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
GlobeNewswire News Room· 2024-10-28 13:31
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that members of its senior leadership team will be presenting and be available for one-on-one meetings with investors at the following upcoming investor conferences. 2024 ThinkEqui ...
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
GlobeNewswire News Room· 2024-10-21 12:30
SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence ( ...
BIO Gears Up for Q3 Earnings: Here's What You Need to Know
ZACKS· 2024-10-17 17:05
Bio-Rad Laboratories, Inc. (BIO) is scheduled to release third-quarter 2024 results on Oct. 30, after the closing bell. The company posted adjusted earnings per share (EPS) of $3.11 in the last reported quarter, which beat the Zacks Consensus Estimate by 46.7%. Bio-Rad beat on earnings in three of the trailing four quarters and missed the same in one, the average surprise being 11.48%. Find the latest EPS estimates and surprises on Zacks Earnings Calendar. BIO's Q3 Estimates The Zacks Consensus Estimate for ...
BIO-key Accelerates Zero Trust Solutions at Industry-Leading Cybersecurity Conference, ISC² Security Congress 2024
GlobeNewswire News Room· 2024-10-14 13:00
LAS VEGAS and HOLMDEL, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring phoneless, tokenless, passwordless and phish-resistant authentication solutions, announced the company will sponsor, speak, and exhibit at ISC2 Security Congress 2024, in Las Vegas on October 14 – 16, 2024. BIO-key will be hosting a session on Passkeys. Passkeys and zero trust are core enabling co ...
Should You Continue to Hold Bio-Rad Stock in Your Portfolio?
ZACKS· 2024-10-01 15:11
Bio-Rad Laboratories, Inc.'s (BIO) robust QX600 Droplet Digital PCR (ddPCR) platform positions the company well to capture a major share in the booming digital PCR space. The clinical diagnostics business continues to gain momentum while building a position in new molecular diagnostics areas. The company's emphasis on international expansion is encouraging. Meanwhile, the persistent softness in the Biopharma segment and negative economic impacts on Bio-Rad's margin performance raise concerns. In the past ye ...